PMDA Medical Device Registration in Japan
Japan ranks as the world's second-largest medical device market, valued at over $30 billion annually. Navigating PMDA regulatory requirements, the PMD Act, and Japan's unique Marketing Authorization Holder framework demands specialized expertise. NexorTest is your trusted Japan medical device approval consultant, guiding international manufacturers through every stage of market entry with precision and regulatory confidence.
PMD Act Compliance
End-to-end guidance for the Pharmaceutical and Medical Device Act, covering all four device classes and three approval pathways in Japan.
MAH Partnership
We connect foreign manufacturers with licensed Marketing Authorization Holders for seamless market access and ongoing regulatory support.
PMDA Fast-Track Ready
Leverage SAKIGAKE designation and priority review pathways for innovative, breakthrough medical devices and digital health products.
Our Japan MedTech Consulting Services
NexorTest delivers comprehensive Japan medical device regulatory consulting services, from initial classification and strategy through PMDA submission, MAH coordination, and post-market obligations.
PMDA Registration Support
Our Japan medical device regulatory consultants manage your complete PMDA submission process, including pre-submission consultations (Taimen Joshu), dossier preparation in CTD format, and liaison with PMDA reviewers. We handle Todokede notifications for Class I devices, Ninshō applications through Registered Certification Bodies for Class II devices, and Shonin applications for Class III and IV devices requiring direct MHLW approval. Our team ensures your technical documentation meets PMDA’s rigorous standards, reducing review queries and accelerating approval timelines.
QMS Compliance (Japan)
Japan’s QMS Ministerial Ordinance (MHLW Ordinance No. 169) requires manufacturers to maintain a quality management system aligned with ISO 13485 but tailored to Japanese-specific requirements. NexorTest provides gap analysis between your existing QMS and Japan’s QMS Ordinance, supports implementation of Japan-specific document control and risk management procedures, and prepares your facility for QMS conformity audits conducted by PMDA or designated audit bodies. We ensure your manufacturing site, whether domestic or international, achieves and sustains full compliance with Japanese quality system regulations.
Clinical Data Strategy
PMDA frequently requires Japan-specific clinical evidence, particularly for Class III and IV medical devices. NexorTest develops clinical data strategies that optimize the balance between leveraging existing international clinical data and generating supplementary Japanese clinical evidence. We advise on the acceptability of foreign clinical trial data, design bridging studies when required, and coordinate with Japanese clinical trial sites and principal investigators. Our clinical regulatory experts also assist with PMDA pre-submission scientific consultations (Taimen Joshu) to confirm clinical data requirements before you commit resources to costly studies.
SaMD & Digital Health
Japan has established dedicated regulatory pathways for Software as a Medical Device (SaMD), AI-based diagnostics, and connected health platforms under the PMD Act. NexorTest provides specialized SaMD regulation Japan PMDA guidance, including classification assessment under Japan’s SaMD framework, preparation of AI/ML algorithm documentation, cybersecurity risk assessments aligned with PMDA’s medical device cybersecurity guidelines, and continuous learning algorithm change management protocols. We help digital health innovators navigate the intersection of software development lifecycle management and PMDA regulatory requirements to bring AI-powered and software-driven devices to market efficiently.
Foreign Manufacturer Registration
All foreign manufacturers exporting medical devices to Japan must obtain a Foreign Manufacturer Registration (FMR) from PMDA before their products can be marketed. NexorTest manages the complete FMR application process, including preparation of manufacturing site information, quality system documentation, product listing details, and coordination of facility audits when required by PMDA. We also facilitate ongoing FMR maintenance, including registration renewals, site change notifications, and product scope expansions to ensure uninterrupted market access for your device portfolio across Japan.
Post-Market Surveillance
Japan’s post-market surveillance (PMS) requirements are among the most comprehensive globally. NexorTest supports MAH holders and foreign manufacturers with vigilance reporting obligations, including adverse event and malfunction reporting to PMDA within mandated timeframes. We design and implement post-market clinical follow-up (PMCF) plans, use-results surveys (Shiyou Seiseki Chousa), periodic safety update reports, and re-examination study protocols required for devices that receive conditional Shonin approval. Our PMS consultants ensure your device maintains continuous compliance throughout its lifecycle in the Japanese market.
Japan Medical Device Classification Under the PMD Act
The Pharmaceutical and Medical Device Act (PMD Act) classifies medical devices into four risk-based classes, each with a distinct regulatory pathway, required documentation, and review timeline managed by PMDA and MHLW.
| Class | Risk Level | Category Name | Pathway | Review Body | Timeline | Examples |
|---|---|---|---|---|---|---|
| Class I | Low | General Medical Devices | Todokede (Notification) | PMDA (Local Prefectural Gov.) | Days to weeks | Tongue depressors, manual stethoscopes, gauze |
| Class II | Medium | Controlled Medical Devices | Ninshō (Third-Party Certification) | Registered Certification Body (RCB) | 3 – 6 months | Powered wheelchairs, dental alloys, ultrasound transducers |
| Class III | High | Specially Controlled Medical Devices | Ninshō or Shonin (MHLW Approval) | RCB or PMDA | 10 – 14 months | Dialysis equipment, orthopedic implants, infusion pumps |
| Class IV | Very High | Specially Controlled Medical Devices | Shonin (MHLW Approval via PMDA) | PMDA (full review) | 12 – 18+ months | Cardiovascular stents, pacemakers, artificial hearts |
Understanding Japan's Approval Pathways
Japan’s three-tiered approval system distinguishes it from most other regulatory jurisdictions. The Todokede pathway is a simple product notification for the lowest-risk devices. The Ninshō pathway leverages Registered Certification Bodies (RCBs) for devices that conform to established JIS standards or MHLW-designated certification criteria, allowing faster review outside of PMDA’s direct review queue. The Shonin pathway is reserved for higher-risk or novel devices that require comprehensive scientific review by PMDA, including full technical documentation, clinical evidence evaluation, and often a QMS audit of the manufacturing facility. Understanding which pathway applies to your device is a critical first step in building an efficient market entry strategy for Japan, and NexorTest’s regulatory consultants provide definitive classification guidance based on our extensive experience with PMDA submissions.
How to Register a Medical Device in Japan
The Japan medical device registration process involves multiple regulatory stages, from initial classification through PMDA approval and NHI reimbursement listing. Here is the complete pathway for international manufacturers.
Device Classification & Gap Analysis
The registration process begins with accurate classification of your medical device under the PMD Act. NexorTest evaluates your device’s intended purpose, technology, and risk profile to determine whether it falls into Class I, II, III, or IV, and identifies the corresponding regulatory pathway: Todokede, Ninshō, or Shonin. We then perform a comprehensive gap analysis comparing your existing regulatory dossier against Japan-specific requirements, identifying documentation that needs to be created, adapted, or translated into Japanese.
Appoint a Marketing Authorization Holder
Foreign manufacturers cannot directly hold a marketing authorization in Japan. You must appoint a licensed MAH (Marketing Authorization Holder) based in Japan who will serve as the legal entity responsible for your device. NexorTest assists in identifying and vetting qualified MAH partners based on their license class (Dai-Ichi-Shu, Dai-Ni-Shu, or Dai-San-Shu), therapeutic area expertise, distribution capabilities, and track record with PMDA. We structure the MAH agreement to protect your intellectual property and ensure clear responsibility allocation for regulatory, quality, and commercial obligations.
Foreign Manufacturer Registration
Before your device can be submitted for approval, your manufacturing facility must be registered as an Accredited Foreign Manufacturer with PMDA. This involves submitting detailed manufacturing site information, quality management system documentation, and product scope details. NexorTest prepares and submits your FMR application, coordinates any required facility audit logistics, and ensures your registration covers all product variants intended for the Japanese market. FMR registration must be maintained and renewed periodically to continue exporting to Japan.
QMS Compliance & Audit Preparation
Japan’s QMS Ministerial Ordinance requires documented compliance with quality system standards that parallel but extend beyond ISO 13485. NexorTest conducts a thorough audit readiness assessment, identifies gaps between your current QMS and Japan’s ordinance requirements, and implements necessary corrective actions. We prepare your team for QMS conformity audits and mock inspections, ensuring your manufacturing site demonstrates full compliance with Japanese quality system expectations before PMDA or an authorized audit body conducts the official assessment.
Dossier Preparation & Submission
NexorTest compiles your regulatory dossier in the format required by PMDA, including product specifications, design and manufacturing documentation, biocompatibility data, electrical safety and EMC test reports referenced against JIS standards, sterilization validation, shelf-life data, and clinical evidence. All documentation must be submitted in Japanese. Our regulatory writers and translators ensure technical accuracy and linguistic precision. For Shonin applications, we also prepare your PMDA pre-submission meeting (Taimen Joshu) materials and manage the iterative review process with PMDA reviewers.
PMDA Review & Approval
Following submission, PMDA conducts a scientific and technical review of your application. For Ninshō pathway submissions, the Registered Certification Body performs the review against established standards. For Shonin applications, PMDA reviewers evaluate the full technical dossier, may request additional data or clarifications, and conduct a QMS audit. NexorTest manages all PMDA correspondence, prepares responses to review queries, and coordinates any supplementary data submissions. Upon successful review, your device receives its marketing authorization from MHLW, enabling lawful distribution throughout Japan.
NHI Reimbursement & Market Launch
Securing National Health Insurance (NHI) reimbursement is essential for commercial success in Japan, as the national healthcare system covers the vast majority of medical device purchases. NexorTest advises on reimbursement category classification, pricing strategy under the NHI fee schedule, and the application process for new technology reimbursement codes. We coordinate with your MAH to prepare the reimbursement application and support negotiations with Japan’s Central Social Insurance Medical Council (Chuikyo) to achieve favorable pricing that supports your commercial objectives in the Japanese market.
Post-Market Surveillance & Maintenance
After market authorization, ongoing compliance requires robust post-market surveillance, adverse event reporting within mandated timeframes, periodic safety update reports, and re-examination studies for conditionally approved devices. NexorTest establishes your PMS framework, trains your MAH team on vigilance reporting procedures, and supports re-examination and re-evaluation processes. We also manage registration renewals, variation applications for device modifications, and FMR maintenance to ensure uninterrupted market access throughout your device’s commercial lifecycle in Japan.
Why Choose NexorTest for Japan Medical Device Registration
Entering the Japanese medical device market requires a regulatory partner with deep local knowledge, proven PMDA experience, and global perspective. Here is what sets NexorTest apart as your Japan medical device regulatory consultant.
Deep Japan Regulatory Expertise
Our regulatory consultants possess extensive experience working within Japan's unique regulatory environment, including PMDA submission practices, QMS Ministerial Ordinance interpretation, and JIS standard mapping. We understand the nuances of PMDA reviewer expectations and Japanese regulatory culture that generic consulting firms simply cannot match.
Established MAH Network
NexorTest maintains a vetted network of licensed Marketing Authorization Holders across all device categories and risk classes. We match manufacturers with MAH partners whose therapeutic area focus, distribution infrastructure, and license class align precisely with your product and commercial strategy, reducing partnership risk and accelerating market entry.
Global Multi-Market Strategy
Most manufacturers seeking PMDA registration are simultaneously pursuing approvals in the EU, US, and other Asian markets. NexorTest leverages common documentation, test reports, and clinical data across jurisdictions, building a harmonized regulatory strategy that minimizes duplication and reduces your total time-to-market across multiple countries, including Japan.
Japanese Language Capability
All PMDA submissions must be in Japanese, a requirement that presents a substantial barrier for international companies. NexorTest provides regulatory-grade Japanese translation services performed by bilingual regulatory affairs professionals who understand medical device terminology and PMDA documentation conventions, ensuring technical accuracy and regulatory compliance in every submitted document.
SAKIGAKE & Fast-Track Access
For innovative and breakthrough medical devices, Japan offers the SAKIGAKE designation program, providing priority PMDA consultation, pre-submission support, and accelerated review timelines. NexorTest evaluates your device's eligibility for SAKIGAKE designation or other priority review pathways and manages the application process to secure faster market access for genuinely innovative medical technologies.
End-to-End Project Management
From initial classification strategy through PMDA approval and NHI reimbursement listing, NexorTest provides a single point of accountability. Our dedicated project managers coordinate all workstreams including documentation, translation, MAH liaison, QMS audits, clinical strategy, and post-market setup, ensuring nothing falls through the cracks in Japan's intricate regulatory process.
Frequently Asked Questions About PMDA Medical Device Registration
Get direct answers to the most common questions about registering medical devices in Japan, PMD Act compliance, MAH requirements, and PMDA approval timelines.
How do I register a medical device in Japan?
To register a medical device in Japan, you must classify your device under the PMD Act (Class I through IV), appoint a Marketing Authorization Holder (MAH) based in Japan, obtain Foreign Manufacturer Registration from PMDA, prepare a QMS-compliant technical dossier in Japanese, and submit to PMDA or a Registered Certification Body depending on the device class. Class I devices require only a Todokede notification, while Class II through IV devices need Ninshō certification or Shonin approval from MHLW.
How long does PMDA medical device approval take?
PMDA medical device approval timelines vary by device classification. Class I Todokede notifications are processed within days to a few weeks. Class II Ninshō certifications through a Registered Certification Body typically take 3 to 6 months. Class III Shonin approvals requiring PMDA review take approximately 10 to 14 months, and Class IV high-risk Shonin approvals can take 12 to 18 months or longer, especially if Japan-specific clinical data is required.
What is a Marketing Authorization Holder (MAH) and why do I need one in Japan?
A Marketing Authorization Holder (MAH) is a Japan-based legal entity responsible for the marketing, distribution, and post-market safety of your medical device. Foreign manufacturers cannot directly market devices in Japan and must partner with a licensed MAH, known as a Dai-Ichi-Shu, Dai-Ni-Shu, or Dai-San-Shu manufacturer-distributor depending on device risk class. The MAH holds the registration license and is accountable to PMDA and MHLW for all regulatory obligations including adverse event reporting.
What is the difference between Todokede, Ninshō, and Shonin pathways?
Todokede is the simplest pathway for Class I general medical devices, requiring only a product notification to PMDA. Ninshō applies to Class II and some Class III devices that match existing JIS or certification standards, reviewed by a Registered Certification Body rather than PMDA directly. Shonin is the most rigorous pathway for Class III and all Class IV devices requiring direct review and approval by PMDA on behalf of MHLW, including full technical review, QMS audit, and often Japan-specific clinical evidence.
Does Japan accept foreign clinical data for medical device registration?
Japan may accept foreign clinical data, but PMDA often requires Japan-specific clinical evidence, particularly for higher-risk Class III and IV devices. Under IMDRF harmonization efforts, PMDA has become more receptive to pivotal clinical data from international multi-center trials that include Japanese patient populations. However, differences in patient demographics and clinical practice patterns may necessitate supplementary Japanese clinical studies or bridging data to support your submission.
What are the SaMD and AI-ML medical device regulations in Japan?
Japan’s PMDA has issued dedicated guidance for Software as a Medical Device (SaMD) and AI/ML-based medical devices, aligning closely with the IMDRF SaMD framework. SaMD products are classified based on intended medical purpose and risk level, and AI-driven devices may require a continuous learning plan and algorithm change management protocol. The PMD Act was updated to accommodate SaMD lifecycle management, including post-market performance monitoring and cybersecurity requirements for connected medical devices.
Start Your Japan Market Entry Today
Whether you are launching a novel SaMD product or seeking Shonin approval for a Class IV implantable device, NexorTest’s Japan medical device regulatory consultants are ready to guide you through every step of PMDA registration and beyond.